Anti-TNF-Alpha Therapy and Systemic Vasculitis

Table 2

Open label trial performed in TA.

References	Design/anti-TNF-α therapy	Number of patients	Main objectives	Follow-up	Main results	Side effects
Hoffman et al. [26]	Open label trial IFX/ETN	15	Remission and discontinuation of corticosteroids	12 months	67% complete remission 27% partial remission (50% of glucocorticoid requirements reduction)	One infusion reaction to IFX